Maria Wessman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Maria Wessman has a total of 141 co-authors. Here are the top co-authors by number of shared publications:
- Anne-Mette Lebech
Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark
2 shared publications - Eline Op de Coul
Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands
2 shared publications Gitte Pedersen
Department of Infectious Diseases, Aalborg University Hospital, Denmark
2 shared publications- Isik Somuncu Johansen
Department of Infectious Diseases, Odense University Hospital
2 shared publications Kristina Thorsteinsson
Department of Infectious Diseases, Copenhagen University Hospital Hvidovre, Denmark
2 shared publications- Marek Malý
Department of Biostatistics, National Institute of Public Health, Prague, Czech Republic
2 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 31 (35) , 2600031
Elimination of congenital syphilis: a nationwide register-based study, Denmark, 2010 to 2024
BACKGROUND: Congenital syphilis is a potentially serious, but preventable infection. Several European countries have recently reported increasing trends. AIM: This study assessed national incidence and temporal trends of congenital syphilis and prevalence of pregnancies with active syphilis in Denmark between 2010 and 2024. METHODS: Using nationwide individual-level data linked through civil registration numbers across Danish health and population registers, we identified all maternal and congenital syphilis cases among live-born children born in Denmark from 2010 to 2024. We calculated annual incidence per 10,000 live births and analysed temporal trends and annual percent change (APC) with 95% confidence intervals (CI), using Poisson or negative binomial regression models. RESULTS: Five infants with confirmed congenital syphilis were recorded among 894,345 live births, corresponding to an incidence of 0.6 per 100,000 (95% CI: 0.2–1.4). No infants with congenital syphilis were identified after 2016. For each infant, a plausible explanation for screening failure was identified: two women arrived in Denmark late in pregnancy, two were infected late in pregnancy. None of these events reflected failure of the first-trimester screening algorithm itself. One event was due to a reporting irregularity. Poisson regression showed a decreasing trend (APC = −21.7%; 95% CI: −43.4 to −1.0). Active syphilis infection occurred in 172 pregnancies, amounting to 20.0 per 100,000 live births (95% CI: 17.2–23.2) with no temporal changes. CONCLUSIONS: Congenital syphilis is now eliminated in Denmark. The incidence of pregnancies with active syphilis infection remained stable despite increasing syphilis prevalence in the general population, confirming the continued effectiveness of the Danish national antenatal syphilis screening programme.
- 3 September 2026
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 31 (35) , 2600031
Open AccessElimination of congenital syphilis: a nationwide register-based study, Denmark, 2010 to 2024
BACKGROUND: Congenital syphilis is a potentially serious, but preventable infection. Several European countries have recently reported increasing trends. AIM: This study assessed national incidence and temporal trends of congenital syphilis and prevalence of pregnancies with active syphilis in Denmark between 2010 and 2024. METHODS: Using nationwide individual-level data linked through civil registration numbers across Danish health and population registers, we identified all maternal and congenital syphilis cases among live-born children born in Denmark from 2010 to 2024. We calculated annual incidence per 10,000 live births and analysed temporal trends and annual percent change (APC) with 95% confidence intervals (CI), using Poisson or negative binomial regression models. RESULTS: Five infants with confirmed congenital syphilis were recorded among 894,345 live births, corresponding to an incidence of 0.6 per 100,000 (95% CI: 0.2–1.4). No infants with congenital syphilis were identified after 2016. For each infant, a plausible explanation for screening failure was identified: two women arrived in Denmark late in pregnancy, two were infected late in pregnancy. None of these events reflected failure of the first-trimester screening algorithm itself. One event was due to a reporting irregularity. Poisson regression showed a decreasing trend (APC = −21.7%; 95% CI: −43.4 to −1.0). Active syphilis infection occurred in 172 pregnancies, amounting to 20.0 per 100,000 live births (95% CI: 17.2–23.2) with no temporal changes. CONCLUSIONS: Congenital syphilis is now eliminated in Denmark. The incidence of pregnancies with active syphilis infection remained stable despite increasing syphilis prevalence in the general population, confirming the continued effectiveness of the Danish national antenatal syphilis screening programme.
- Open Access
- 13 August 2026
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 31 (32) , 2500921
Multi-country study on the impact of a revised consensus definition of late HIV diagnosis, Europe, 2022 to 2023
BACKGROUND: With improvements in test sensitivity and testing frequency, more people in Europe are diagnosed during the HIV acute/seroconversion phase, when their CD4 + T-cell count can be temporarily low. AIM: We piloted a revised definition of late HIV diagnosis for surveillance which considers laboratory markers, evidence of HIV test negativity in the past year and clinical evidence of recent HIV acquisition, to better distinguish between people diagnosed late and those diagnosed during the acute/seroconversion phase. METHODS: We collected pseudonymised HIV diagnosis records for 2022 and 2023 from nine European countries (Belgium, Czechia, Denmark, Germany, Greece, Italy, the Netherlands, Portugal and Sweden). We applied the revised definition to reclassify those with evidence of recently acquired HIV as 'not late' and calculated the corresponding correction factor by country and demographic group. Individuals with a previous diagnosis were excluded from the analysis. RESULTS: Among 10,220 individuals with a CD4 + T-cell count at diagnosis, 56% (5,689/10,220) had a CD4 + T-cell count < 350 cells/µL or an AIDS-defining event at diagnosis. Applying the revised definition reduced the late diagnosis proportion from 56% to 50%, a correction factor of 9% (535/5,689). The correction factor ranged between 3% and 25% across countries and was higher for younger ages and for gay, bisexual and other men who have sex with men, compared with other groups. CONCLUSIONS: Without reclassification, late HIV diagnosis proportions are overestimated. We provide recommendations and validity considerations for countries intending to use the revised definition.
- 13 August 2026
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 31 (32) , 2500921
Open AccessMulti-country study on the impact of a revised consensus definition of late HIV diagnosis, Europe, 2022 to 2023
BACKGROUND: With improvements in test sensitivity and testing frequency, more people in Europe are diagnosed during the HIV acute/seroconversion phase, when their CD4 + T-cell count can be temporarily low. AIM: We piloted a revised definition of late HIV diagnosis for surveillance which considers laboratory markers, evidence of HIV test negativity in the past year and clinical evidence of recent HIV acquisition, to better distinguish between people diagnosed late and those diagnosed during the acute/seroconversion phase. METHODS: We collected pseudonymised HIV diagnosis records for 2022 and 2023 from nine European countries (Belgium, Czechia, Denmark, Germany, Greece, Italy, the Netherlands, Portugal and Sweden). We applied the revised definition to reclassify those with evidence of recently acquired HIV as 'not late' and calculated the corresponding correction factor by country and demographic group. Individuals with a previous diagnosis were excluded from the analysis. RESULTS: Among 10,220 individuals with a CD4 + T-cell count at diagnosis, 56% (5,689/10,220) had a CD4 + T-cell count < 350 cells/µL or an AIDS-defining event at diagnosis. Applying the revised definition reduced the late diagnosis proportion from 56% to 50%, a correction factor of 9% (535/5,689). The correction factor ranged between 3% and 25% across countries and was higher for younger ages and for gay, bisexual and other men who have sex with men, compared with other groups. CONCLUSIONS: Without reclassification, late HIV diagnosis proportions are overestimated. We provide recommendations and validity considerations for countries intending to use the revised definition.
- Open Access
- 24 July 2026
- Published by Taylor & Francis in Infectious Diseases
- p. 1-11
Diagnosis and treatment coverage among hepatitis C infections in Denmark, 2022: a capture-recapture study using national registers
- 24 July 2026
- Published by Taylor & Francis in Infectious Diseases
- p. 1-11
Open AccessDiagnosis and treatment coverage among hepatitis C infections in Denmark, 2022: a capture-recapture study using national registers
- Open Access
- 9 April 2026
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 31 (14) , 2500322
Use of the Workbook Method to estimate the prevalence of chronic hepatitis B infections in the European Union and European Economic Area, 2022
BACKGROUND: Up-to-date estimates of chronic hepatitis B virus (HBV) prevalence in both general and key populations are challenging to obtain because of underdiagnosis, heterogeneous surveillance systems and underrepresentation of key populations. AIM: We aimed to test the Workbook Method to estimate chronic HBV prevalence in 2022 across the EU/EEA, by country and among men who have sex with men (MSM), people who inject drugs (PWID) and migrants. METHODS: We used the Robert Koch Institute’s version of the Joint United Nations Programme on HIV/AIDS (UNAIDS) Workbook Method to generate HBV prevalence estimates for each EU/EEA country and for MSM, PWID and migrants within each country. We combined data on population size and HBV prevalence for each population group gathered from scientific sources and reviewed by the European Centre for Disease Prevention and Control’s hepatitis national contact points. RESULTS: Overall, 0.7% (lower bound–upper bound: 0.5–0.9%) of the EU/EEA population (3,226,000 (2,397,000–4,149,000) individuals) were estimated to be living with HBV in 2022. National HBV prevalence ranged from 0.1% (0.1–1.0%) to 3.1% (2.8–3.3%). Prevalence estimates varied from 0.8% (0.5–1.0%) to 10.5% (9.3–11.9%) for migrants, < 0.1% to 8.7% (lower and upper bounds not available) for PWID and from < 0.1% (< 0.1– < 0.1%) to 10.5% (10.2–10.8%) for MSM. DISCUSSION: Despite limitations, including the inability to address overlapping populations, these estimates confirm substantial chronic HBV prevalence in the EU/EEA, with considerable variation between countries and population groups. This relatively straightforward method offers an alternative means of generating HBV prevalence estimates.
- 9 April 2026
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 31 (14) , 2500322
Open AccessUse of the Workbook Method to estimate the prevalence of chronic hepatitis B infections in the European Union and European Economic Area, 2022
BACKGROUND: Up-to-date estimates of chronic hepatitis B virus (HBV) prevalence in both general and key populations are challenging to obtain because of underdiagnosis, heterogeneous surveillance systems and underrepresentation of key populations. AIM: We aimed to test the Workbook Method to estimate chronic HBV prevalence in 2022 across the EU/EEA, by country and among men who have sex with men (MSM), people who inject drugs (PWID) and migrants. METHODS: We used the Robert Koch Institute’s version of the Joint United Nations Programme on HIV/AIDS (UNAIDS) Workbook Method to generate HBV prevalence estimates for each EU/EEA country and for MSM, PWID and migrants within each country. We combined data on population size and HBV prevalence for each population group gathered from scientific sources and reviewed by the European Centre for Disease Prevention and Control’s hepatitis national contact points. RESULTS: Overall, 0.7% (lower bound–upper bound: 0.5–0.9%) of the EU/EEA population (3,226,000 (2,397,000–4,149,000) individuals) were estimated to be living with HBV in 2022. National HBV prevalence ranged from 0.1% (0.1–1.0%) to 3.1% (2.8–3.3%). Prevalence estimates varied from 0.8% (0.5–1.0%) to 10.5% (9.3–11.9%) for migrants, < 0.1% to 8.7% (lower and upper bounds not available) for PWID and from < 0.1% (< 0.1– < 0.1%) to 10.5% (10.2–10.8%) for MSM. DISCUSSION: Despite limitations, including the inability to address overlapping populations, these estimates confirm substantial chronic HBV prevalence in the EU/EEA, with considerable variation between countries and population groups. This relatively straightforward method offers an alternative means of generating HBV prevalence estimates.
- Top Cited PapersOpen Access
- 13 June 2024
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 29 (24) , 2400299
Epidemic of parvovirus B19 and disease severity in pregnant people, Denmark, January to March 2024
We report an epidemic of parvovirus B19 infections in Denmark during the first quarter of 2024, with a peak incidence 3.5 times higher than during the most recent epidemic in 2017. In total, 20.1% (130/648) of laboratory-confirmed cases were pregnant. Severe adverse outcomes were observed among 12.3% (16/130) of pregnant people and included foetal anaemia, foetal hydrops and miscarriage. Parvovirus B19 infection is not systematically monitored, but a national laboratory-based surveillance system is currently being established in Denmark.
- 13 June 2024
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 29 (24) , 2400299
Top Cited PapersOpen AccessEpidemic of parvovirus B19 and disease severity in pregnant people, Denmark, January to March 2024
We report an epidemic of parvovirus B19 infections in Denmark during the first quarter of 2024, with a peak incidence 3.5 times higher than during the most recent epidemic in 2017. In total, 20.1% (130/648) of laboratory-confirmed cases were pregnant. Severe adverse outcomes were observed among 12.3% (16/130) of pregnant people and included foetal anaemia, foetal hydrops and miscarriage. Parvovirus B19 infection is not systematically monitored, but a national laboratory-based surveillance system is currently being established in Denmark.
- Open Access
- 15 February 2024
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 29 (7) , 2400059
Gonorrhoea on the rise in Denmark since 2022: distinct clones drive increase in heterosexual individuals
A surge in gonorrhoea in Denmark has occurred since 2022, a 46% increase from 2021. National surveillance, leveraging mandatory reporting and epidemiological data, highlights three distinct clades linked to heterosexual transmission. Despite the rise, these exhibit high susceptibility, contrasting MSM-associated strains. Geographical hotspots and age-specific patterns further illuminate transmission dynamics. The combination of genomic and epidemiological data provides novel insights into the evolving landscape of gonorrhoea, indicating potential shifts in infection dynamics and transmissibility.
- 15 February 2024
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 29 (7) , 2400059
Open AccessGonorrhoea on the rise in Denmark since 2022: distinct clones drive increase in heterosexual individuals
A surge in gonorrhoea in Denmark has occurred since 2022, a 46% increase from 2021. National surveillance, leveraging mandatory reporting and epidemiological data, highlights three distinct clades linked to heterosexual transmission. Despite the rise, these exhibit high susceptibility, contrasting MSM-associated strains. Geographical hotspots and age-specific patterns further illuminate transmission dynamics. The combination of genomic and epidemiological data provides novel insights into the evolving landscape of gonorrhoea, indicating potential shifts in infection dynamics and transmissibility.
- Open Access
- 1 July 2017
- Published by Elsevier in Journal of Virus Eradication
- Vol. 3 (3) , 140-144
HIV disclosure and stigma among women living with HIV in Denmark
- 1 July 2017
- Published by Elsevier in Journal of Virus Eradication
- Vol. 3 (3) , 140-144
Open AccessHIV disclosure and stigma among women living with HIV in Denmark
- Open Access
- 31 May 2017
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 17 (1) , 1-10
Bacterial vaginosis, human papilloma virus and herpes viridae do not predict vaginal HIV RNA shedding in women living with HIV in Denmark
Bacterial vaginosis (BV) has been found to be associated with HIV acquisition and transmission. This is suggested to be due to higher HIV RNA levels in cervicovaginal fluids in women living with HIV (WLWH) with BV, as bacteria associated with BV may induce viral replication and shedding in the genital tract despite undetectable HIV RNA plasma viral load. We examined the prevalence and diagnostic predictors of BV and HIV-1 RNA vaginal shedding in women living with HIV (WLWH) in Denmark, taking into account the presence of human papillomavirus (HPV) and herpes viridae. WLWH between 18–51 years were recruited from six Departments of Infectious Diseases in Denmark during enrolment in the SHADE cohort; a prospective cohort study of WLWH attending regular outpatient care. BV was diagnosed by microscopy of vaginal swabs and PCR was used for detection of BV-associated bacteria, HPV, herpes viridae, and vaginal HIV viral load. Median age of the 150 included women was 41 years; ethnicity was predominantly White (35%) or Black (47%). The majority (96%) was on ART and had undetectable (85%) plasma HIV RNA (<40 copies/mL). BV was diagnosed in 32%. Overall, 11% had detectable vaginal HIV RNA. Both before and after adjustment for BV, age, ethnicity, plasma HIV RNA, CD4 cell count, herpes viridae and HPV, we found no significant predictors of HIV RNA vaginal shedding. In well-treated WLWH, BV, herpes viridae or HPV do not predict vaginal HIV RNA shedding. This implies that HIV shedding does not seem to be increased by BV.
- 31 May 2017
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 17 (1) , 1-10
Open AccessBacterial vaginosis, human papilloma virus and herpes viridae do not predict vaginal HIV RNA shedding in women living with HIV in Denmark
Bacterial vaginosis (BV) has been found to be associated with HIV acquisition and transmission. This is suggested to be due to higher HIV RNA levels in cervicovaginal fluids in women living with HIV (WLWH) with BV, as bacteria associated with BV may induce viral replication and shedding in the genital tract despite undetectable HIV RNA plasma viral load. We examined the prevalence and diagnostic predictors of BV and HIV-1 RNA vaginal shedding in women living with HIV (WLWH) in Denmark, taking into account the presence of human papillomavirus (HPV) and herpes viridae. WLWH between 18–51 years were recruited from six Departments of Infectious Diseases in Denmark during enrolment in the SHADE cohort; a prospective cohort study of WLWH attending regular outpatient care. BV was diagnosed by microscopy of vaginal swabs and PCR was used for detection of BV-associated bacteria, HPV, herpes viridae, and vaginal HIV viral load. Median age of the 150 included women was 41 years; ethnicity was predominantly White (35%) or Black (47%). The majority (96%) was on ART and had undetectable (85%) plasma HIV RNA (<40 copies/mL). BV was diagnosed in 32%. Overall, 11% had detectable vaginal HIV RNA. Both before and after adjustment for BV, age, ethnicity, plasma HIV RNA, CD4 cell count, herpes viridae and HPV, we found no significant predictors of HIV RNA vaginal shedding. In well-treated WLWH, BV, herpes viridae or HPV do not predict vaginal HIV RNA shedding. This implies that HIV shedding does not seem to be increased by BV.
- Open Access
- 1 January 2015
- Published by Wiley in Journal of the International AIDS Society
- Vol. 18 (1) , 19962
Perception of sexuality and fertility in women living with HIV: a questionnaire study from two Nordic countries
Introduction: As the human immunodeficiency virus (HIV)‐positive population ages, issues concerning sexuality and fertility, among others, are becoming relevant. HIV is still surrounded by stigma and taboos, and there have been few studies conducted in industrialized settings concerning these questions. We therefore wanted to investigate the perception of sexuality and fertility in women living with HIV (WLWH) in an industrialized setting, using a questionnaire.Methods: WLWH were recruited at their regular outpatient clinic visits, at the major Departments of Infectious Diseases in Denmark and Finland, from January 2012 to October 2013. A questionnaire was developed, study participants were informed of the nature of study and, if they agreed to participate and signed a consent form, they filled in the questionnaire. Demographic information on the participants was obtained from patient files (in Finland) or from a national HIV cohort (in Denmark). Statistical analysis was performed using STATA®, version 11.Results: In total, 560 women were included in the study. The median age was 44 years. The majority were of white European origin, with fully suppressed HIV viral load, CD4 cell count >350 µL and mild or no symptoms of their HIV infection. A total of 62% were sexually active, stating condom use as their sole form of contraception. Of the sexually inactive women, one‐third were in steady relationships. Eighty percent reported prior pregnancies, of which the majority had one or more children. Most children were born prior to the women's HIV diagnosis and the mode of conception was predominantly natural. One‐quarter of the participating women desired pregnancy, while more than half did not. The remaining quarter either stated that they already had the desired number of children or chose not to answer the question. Fourteen percent stated that their HIV diagnosis ended their wish for children; of these women, the median time of diagnosis was between 1995 and 1996. Pregnancy had been attempted unsuccessfully in one‐quarter of study participants. The final question inquired what the risk of mother‐to‐child transmission was, with all precautions taken. Fifteen percent estimated the risk to be above two percent.Conclusions: In conclusion, the majority of WLWH in industrialized settings in Denmark and Finland have few HIV‐related symptoms, are sexually active and have a strong desire for children.
- 1 January 2015
- Published by Wiley in Journal of the International AIDS Society
- Vol. 18 (1) , 19962
Open AccessPerception of sexuality and fertility in women living with HIV: a questionnaire study from two Nordic countries
Introduction: As the human immunodeficiency virus (HIV)‐positive population ages, issues concerning sexuality and fertility, among others, are becoming relevant. HIV is still surrounded by stigma and taboos, and there have been few studies conducted in industrialized settings concerning these questions. We therefore wanted to investigate the perception of sexuality and fertility in women living with HIV (WLWH) in an industrialized setting, using a questionnaire.Methods: WLWH were recruited at their regular outpatient clinic visits, at the major Departments of Infectious Diseases in Denmark and Finland, from January 2012 to October 2013. A questionnaire was developed, study participants were informed of the nature of study and, if they agreed to participate and signed a consent form, they filled in the questionnaire. Demographic information on the participants was obtained from patient files (in Finland) or from a national HIV cohort (in Denmark). Statistical analysis was performed using STATA®, version 11.Results: In total, 560 women were included in the study. The median age was 44 years. The majority were of white European origin, with fully suppressed HIV viral load, CD4 cell count >350 µL and mild or no symptoms of their HIV infection. A total of 62% were sexually active, stating condom use as their sole form of contraception. Of the sexually inactive women, one‐third were in steady relationships. Eighty percent reported prior pregnancies, of which the majority had one or more children. Most children were born prior to the women's HIV diagnosis and the mode of conception was predominantly natural. One‐quarter of the participating women desired pregnancy, while more than half did not. The remaining quarter either stated that they already had the desired number of children or chose not to answer the question. Fourteen percent stated that their HIV diagnosis ended their wish for children; of these women, the median time of diagnosis was between 1995 and 1996. Pregnancy had been attempted unsuccessfully in one‐quarter of study participants. The final question inquired what the risk of mother‐to‐child transmission was, with all precautions taken. Fifteen percent estimated the risk to be above two percent.Conclusions: In conclusion, the majority of WLWH in industrialized settings in Denmark and Finland have few HIV‐related symptoms, are sexually active and have a strong desire for children.